In this video health care analysts David Williamson and Max Macaluso discuss Pfizer's just-released third-quarter earnings. David distills the highlights and hits on all of the critical takeaways for investors, including potential blockbuster Eliquis shared with Bristol-Myers Squibb and the "bapi" Alzheimer's failure, which it shares with Elan. Watch and discover everything you need to know about Pfizer's most recent quarter.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.